Chronic migraine is unfortunately both common and often resistant to treatment even with prophylactic medications known to be effective in populations with episodic migraine. We undertook an open-label study to evaluate the safety and utility of botulinum toxin type A injection therapy for patients with chronic migraine who previously had failed to respond to at least three prophylactic medications.